Granpidam: A generic to Sildenafil (Revatio)

Last Updated on

September 22, 2016 – The pharmacologically active compound known as sildenafil is largely used to treat erectile dysfunction (on the market for this indication under the trade name Viagra) and pulmonary arterial hypertension (on the market for this indication under the trade name Revatio) in the United

Not a case of pulmonary arterial hypertension (PAH)

Not a case of pulmonary arterial hypertension (PAH)

States (US), the European Union (EU), and many other countries worldwide. Sildenafil, a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary arterial hypertension this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation.

On 15 September 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Granpidam, intended for the treatment of pulmonary arterial hypertension. As such, Granpidam is considered a generic of Revatio, which has been authorised in the EU since 2005. The indications for Granpidam are in adults the “treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity, and in the paediatric population the “treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension”. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease, and in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

What is strange in this context is the fact that apparently the “bioequivalence” of Granpidam has been determined against the Viagra and its indication “erectile dysfunction” as the reference medication that has already been on the market for a long time, and of which all the behaviours of the medication in the population in the main indication should be known. Apparently here, for Granpidam, “bioequivalence” was not determined against its intended indication “primary pulmonary hypertension”, and Revatio as the reference medication. Strange in the light of the fact that the indication of Granpidam is also for paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension, where one would expect that erectile dysfunction would not play any role as a reference indication. One can only hope that the company has sound paediatric risk management plans (RMP) for paediatric patients in place and that previous or still valid paediatric investigation plans (PIP) are being adhered to.

You may also want have a look at the stance of the American Food & Drug Administration (FDA) on the use of Sildenafil (Revatio) in children. Thasso Post has an earlier report on this.

Tags: , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • New therapy stops seizures in mouse model of rare childhood epilepsy February 20, 2020
    Seizure disorders in babies are frightening and heartbreaking. A new basic science breakthrough offers hope for a potential treatment for rare developmental and epileptic encephalopathies resulting from a single genetic mutation. The gene in question, called SCN8A, controls a sodium channel that allows neurons to transmit an electric signal. When this gene is mutated, these […]
  • Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers' February 20, 2020
    A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as "drivers"—variations in DNA sequences that lead to the development of cancer.
  • A deep dive into cellular aging February 20, 2020
    Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell's nucleus—and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes & Development, could lead […]
  • New model of C. elegans helps progress study of rare genetic disease February 20, 2020
    The IDIBELL Neurometabolic Diseases group, with international collaboration, has identified a model of chromosome X-linked adrenoleukodystrophy (X-ALD) in C. elegans. X-ALD is a rare disorder of the nervous system with no available treatment.
  • Half of transgender youth avoid disclosing gender identity to a health care provider February 20, 2020
    Researchers surveyed 153 transgender youths receiving gender-affirming care at a specialty clinic, and even in this relatively 'out' population, nearly half reported intentionally hiding their gender identity from a health care provider outside the clinic.
  • Fifty years of data show new changes in bird migration February 20, 2020
    A growing body of research shows that birds' spring migration has been getting earlier and earlier in recent decades. New research from The Auk: Ornithological Advances on Black-throated Blue Warblers, a common songbird that migrates from Canada and the eastern US to Central America and back every year, uses fifty years of bird-banding data to […]
  • New study supports the safety of varenicline February 20, 2020
    A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT). These findings confirm those of earlier clinical trials, providing […]
  • New study indicates amino acid may be useful in treating ALS February 20, 2020
    A naturally occurring amino acid is gaining attention as a possible treatment for ALS following a new study published in the Journal of Neuropathology & Experimental Neurology. It showed the amino acid, L-serine, successfully reduced ALS-like changes in an animal model of ALS. After exposure to the cyanobacterial neurotoxin, BMAA, vervets developed pathology similar to […]
  • Patients frequently refuse insulin therapy, delaying blood sugar control February 20, 2020
    Investigators from Brigham and Women's Hospital find that more than 40% of patients refuse a physician's recommendation of insulin therapy. The study also finds that patients who decline insulin therapy had worse blood sugar control and it took them significantly longer to lower their blood sugar levels than patients who began insulin therapy.
Top